Amylyx Pharmaceuticals (AMLX) Receivables - Other (2022 - 2026)

Amylyx Pharmaceuticals' Receivables - Other history runs 5 years deep, the most recent figure standing at $100000.0 for Q1 2026.

• In Q1 2026, Receivables - Other changed 0.0% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $100000.0 (changed 0.0% YoY), while the FY2025 annual figure was $100000.0, changed 0.0% from the prior year.
• Receivables - Other was $100000.0 for Q1 2026 at Amylyx Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $800000.0 in Q2 2023 to a low of $100000.0 in Q3 2023.
• Historically, Receivables - Other has averaged $235714.3 across 5 years, with a median of $100000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other changed 0.0% in 2023, then slumped 87.5% in 2024.
• A 5-year view of Receivables - Other shows it stood at $500000.0 in 2022, then changed by 0.0% to $500000.0 in 2023, then plunged by 80.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
• The last three Receivables - Other figures came in at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.